This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lochrie, M. A.
Right arrow Articles by Colosi, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lochrie, M. A.
Right arrow Articles by Colosi, P.

 Previous Article  |  Next Article 

Journal of Virology, January 2006, p. 821-834, Vol. 80, No. 2
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.2.821-834.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Mutations on the External Surfaces of Adeno-Associated Virus Type 2 Capsids That Affect Transduction and Neutralization

Michael A. Lochrie,* Gwen P. Tatsuno, Brian Christie, Jennifer Wellman McDonnell, Shangzhen Zhou, Richard Surosky, Glenn F. Pierce, and Peter Colosi

Avigen, Inc., 1301 Harbor Bay Parkway, Alameda, California 94502-6541

Received 27 May 2005/ Accepted 24 October 2005

Mutations were made at 64 positions on the external surface of the adeno-associated virus type 2 (AAV-2) capsid in regions expected to bind antibodies. The 127 mutations included 57 single alanine substitutions, 41 single nonalanine substitutions, 27 multiple mutations, and 2 insertions. Mutants were assayed for capsid synthesis, heparin binding, in vitro transduction, and binding and neutralization by murine monoclonal and human polyclonal antibodies. All mutants made capsid proteins within a level about 20-fold of that made by the wild type. All but seven mutants bound heparin as well as the wild type. Forty-two mutants transduced human cells at least as well as the wild type, and 10 mutants increased transducing activity up to ninefold more than the wild type. Eighteen adjacent alanine substitutions diminished transduction from 10- to 100,000-fold but had no effect on heparin binding and define an area (dead zone) required for transduction that is distinct from the previously characterized heparin receptor binding site. Mutations that reduced binding and neutralization by a murine monoclonal antibody (A20) were localized, while mutations that reduced neutralization by individual human sera or by pooled human, intravenous immunoglobulin G (IVIG) were dispersed over a larger area. Mutations that reduced binding by A20 also reduced neutralization. However, a mutation that reduced the binding of IVIG by 90% did not reduce neutralization, and mutations that reduced neutralization by IVIG did not reduce its binding. Combinations of mutations did not significantly increase transduction or resistance to neutralization by IVIG. These mutations define areas on the surface of the AAV-2 capsid that are important determinants of transduction and antibody neutralization.


* Corresponding author. Present address: 3374 Creekview Court, Hayward, CA 94541-3581. Phone: (510) 881-1478. Fax: (510) 748-7136. E-mail: mlochrie{at}yahoo.com.


Journal of Virology, January 2006, p. 821-834, Vol. 80, No. 2
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.2.821-834.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P., Nam, H.-J., Agbandje-McKenna, M., Wilson, J. M. (2009). Adeno-Associated Virus Capsid Structure Drives CD4-Dependent CD8+ T Cell Response to Vector Encoded Proteins. J. Immunol. 182: 6051-6060 [Abstract] [Full Text]  
  • Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., Kay, M. A. (2008). In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses. J. Virol. 82: 5887-5911 [Abstract] [Full Text]  
  • DiPrimio, N., Asokan, A., Govindasamy, L., Agbandje-McKenna, M., Samulski, R. J. (2008). Surface Loop Dynamics in Adeno-Associated Virus Capsid Assembly. J. Virol. 82: 5178-5189 [Abstract] [Full Text]  
  • Nam, H.-J., Lane, M. D., Padron, E., Gurda, B., McKenna, R., Kohlbrenner, E., Aslanidi, G., Byrne, B., Muzyczka, N., Zolotukhin, S., Agbandje-McKenna, M. (2007). Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector. J. Virol. 81: 12260-12271 [Abstract] [Full Text]  
  • Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., Agbandje-McKenna, M. (2006). Structurally Mapping the Diverse Phenotype of Adeno-Associated Virus Serotype 4. J. Virol. 80: 11556-11570 [Abstract] [Full Text]  
  • Wu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., Samulski, R. J. (2006). Single Amino Acid Changes Can Influence Titer, Heparin Binding, and Tissue Tropism in Different Adeno-Associated Virus Serotypes. J. Virol. 80: 11393-11397 [Abstract] [Full Text]  
  • Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., Mingozzi, F., High, K. A., Pierce, G. F. (2006). Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108: 3321-3328 [Abstract] [Full Text]  
  • Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., Kay, M. A. (2006). The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9. J. Virol. 80: 9831-9836 [Abstract] [Full Text]  
  • Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., Samulski, R. J. (2006). Adeno-Associated Virus Type 2 Contains an Integrin {alpha}5{beta}1 Binding Domain Essential for Viral Cell Entry.. J. Virol. 80: 8961-8969 [Abstract] [Full Text]